| Comparators
| Nausea OR (95% CI) | Vomiting OR (95%CI) | Diarrhea OR (95% CI) | Direct | MTC | Direct | MTC | Direct | MTC |
| EX10BID versus | | | | | | | EX5BID | 1.90
(1.36, 2.65) | 2.28
(1.26, 4.11) | 1.00 (0.61, 1.63) | 1.20 (0.61, 2.38) | 1.16 (0.71, 1.88) | 1.07 (0.60, 1.89) | EX2QW | 2.16 (0.98, 4.79) | 2.78
(1.25, 6.18) | 1.92
(1.10, 3.36) | 1.88 (0.76, 4.67) | 0.70 (0.31, 1.57) | 0.82 (0.41, 1.64) | LIR0.6 | — | 3.19
(1.14, 8.98) | — | 1.51 (0.49, 4.61) | — | 1.02 (0.45, 2.32) | LIR1.2 | — | 2.16
(1.00, 4.67) | — | 1.37 (0.58, 3.24) | — | 0.77 (0.40, 1.49) | LIR1.8 | 1.14 (0.75, 1.71) | 2.24
(1.11, 4.51) | 1.74 (0.87, 3.47) | 1.35 (0.63, 2.88) | 0.98 (0.56, 1.70) | 0.83 (0.47, 1.47) | CT | 19.36
(10.41, 35.98) | 18.34
(10.54, 31.92) | 5.52
(3.70, 8.23) | 7.78
(4.29, 14.12) | 2.23
(1.54, 3.23) | 2.26
(1.43, 3.58) | Placebo | 6.10
(4.09, 9.11) | 8.05
(5.15, 12.57) | 4.45
(2.88, 6.88) | 7.35
(4.03, 13.40) | 1.99
(1.35, 2.94) | 2.25
(1.45, 3.51) |
| EX2QW versus | | | | | | | EX5BID | — | 0.82 (0.31, 2.17) | — | 0.64 (0.21, 1.97) | — | 1.31 (0.54, 3.18) | LIR0.6 | — | 1.15 (0.34, 3.93) | — | 0.80 (0.20, 3.16) | — | 1.25 (0.46, 3.39) | LIR1.2 | — | 0.78 (0.28, 2.15) | — | 0.73 (0.23, 2.33) | — | 0.94 (0.40, 2.23) | LIR1.8 | | 0.80 (0.30, 2.12) | — | 0.72 (0.24, 2.14) | — | 1.02 (0.45, 2.29) | CT | 5.07
(1.43, 18.04) | 6.60
(2.90, 15.01) | 4.26
(1.83, 9.90) | 4.14
(1.63, 10.49) | 2.23
(1.33, 3.74) | 2.76
(1.38, 5.54) | Placebo | 2.18 (0.33, 14.36) | 2.89
(1.22, 6.89) | 0.94 (0.02, 50.31) | 3.91
(1.35, 11.32) | | 2.76
(1.25, 6.09) |
| EX5BID versus | | | | | | | LIR0.6 | — | 1.40 (0.44, 4.47) | — | 1.26 (0.35, 4.56) | — | 0.96 (0.36, 2.53) | LIR1.2 | — | 0.95 (0.37, 2.42) | — | 1.14 (0.39, 3.33) | — | 0.72 (0.31, 1.68) | LIR1.8 | — | 0.98 (0.41, 2.36) | — | 1.12 (0.42, 3.01) | — | 0.78 (0.36, 1.70) | CT | — | 8.05
(3.69, 17.56) | — | 6.48
(2.69, 15.60) | — | 2.12
(1.04, 4.31) | Placebo | 3.41
(2.08, 5.57) | 3.53
(1.89, 6.59) | 3.76
(2.25, 6.28) | 6.12
(2.81, 13.33) | 1.90
(1.22, 2.96) | 2.11
(1.14, 3.91) |
| LIR0.6 versus | | | | | | | LIR1.2 | 0.77 (0.53, 1.11) | 0.68 (0.26, 1.77) | 0.89 (0.56, 1.43) | 0.91 (0.34, 2.39) | 0.93 (0.61, 1.42) | 0.75 (0.35, 1.60) | LIR1.8 | 0.61
(0.43, 0.87) | 0.70 (0.27, 1.80) | 0.61
(0.38, 0.97) | 0.89 (0.34, 2.34) | 0.70 (0.49, 1.01) | 0.81 (0.39, 1.69) | CT | 4.28
(2.23, 8.22) | 5.74
(2.16, 15.23) | 7.53
(1.85, 30.72) | 5.15
(1.78, 14.87) | 1.83
(1.13, 2.98) | 2.21
(1.05, 4.64) | Placebo | 3.28
(1.24, 8.69) | 2.52 (0.88, 7.20) | 21.20
(1.27, 354.20) | 4.87
(1.45, 16.35) | 3.41
(1.29, 9.00) | 2.20 (0.94, 5.17) |
| LIR1.2 versus | | | | | | | LIR1.8 | 0.86(0.51,1.45) | 1.04 (0.56, 1.91) | 0.79 (0.48, 1.30) | 0.98 (0.52, 1.86) | 0.76 (0.59, 0.99) | 1.08 (0.63, 1.85) | CT | 4.91
(2.68, 8.99) | 8.49
(4.26, 16.92) | 4.43
(2.01, 9.76) | 5.68
(2.61, 12.36) | 1.93
(1.34, 2.78) | 2.93
(1.67, 5.14) | Placebo | 5.37
(2.42, 11.95) | 3.73
(1.67, 8.30) | 14.96
(2.02, 110.78) | 5.36
(2.01, 14.33) | 4.80 (0.93, 24.77) | 2.92
(1.44, 5.96) |
| LIR1.8 versus | | | | | | | CT | 6.11
(4.44, 8.41) | 8.20
(4.39, 15.31) | 5.06
(2.27, 11.29) | 5.76
(2.93, 11.36) | 2.59
(1.92, 3.49) | 2.71
(1.67, 4.41) | Placebo | 2.80 (0.65, 12.09) | 3.60
(1.74, 7.46) | 3.12 (0.48, 20.44) | 5.45
(2.27, 13.09) | 2.82
(1.35, 5.89) | 2.71
(1.45, 5.05) |
|
|